Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas
Status:
Completed
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if intravenous BCX-1777 can be given safely to
improve relapsed or refractory aggressive T-cell leukemias and lymphomas.